Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
Non-small cell lung cancer (NSCLC) driven by activating mutations in epidermal growth factor receptor (EGFR) constitutes up to 10% of NSCLC cases. According to the NCCN recommendations, all patients (with the exception of smoking patients with squamous cell lung cancer) should be screened for the pr...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Termedia Publishing House
2017-09-01
|
| Serie: | Contemporary Oncology |
| Soggetti: | |
| Accesso online: | https://www.termedia.pl/Osimertinib-effective-treatment-of-NSCLC-with-activating-EGFR-mutations-after-progression-on-EGFR-tyrosine-kinase-inhibitors,3,30597,1,1.html |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|